Modality
Vaccine
MOA
HPK1i
Target
SGLT2
Pathway
Incretin
GIST
Development Pipeline
Preclinical
~Oct 2012
→ ~Jan 2014
Phase 1
~Apr 2014
→ ~Jul 2015
Phase 2
~Oct 2015
→ ~Jan 2017
Phase 3
Apr 2017
→ Dec 2030
Phase 3Current
NCT08590328
2,737 pts·GIST
2023-05→2026-06·Terminated
NCT07646653
2,486 pts·GIST
2017-04→2030-12·Completed
NCT05635659
2,190 pts·GIST
2021-01→2028-09·Not yet recruiting
7,413 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-06-263mo awayPh3 Readout· GIST
2028-09-122.5y awayPh3 Readout· GIST
2030-12-154.7y awayPh3 Readout· GIST
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Complet…
P3
Not yet…
P3
Termina…
Catalysts
Ph3 Readout
2026-06-26 · 3mo away
GIST
Ph3 Readout
2028-09-12 · 2.5y away
GIST
Ph3 Readout
2030-12-15 · 4.7y away
GIST
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08590328 | Phase 3 | GIST | Terminated | 2737 | LiverFat |
| NCT07646653 | Phase 3 | GIST | Completed | 2486 | EASI-75 |
| NCT05635659 | Phase 3 | GIST | Not yet recr... | 2190 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 |